Jian-jun, L., Chang-nan, J., Min-lin, Z. et al. Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation., Chin. J. Integr. Med. 11, 104–110 (2005). https://doi.org/10.1007/BF02836465
Lin Jian-jun, Jin Chang-nan, Zheng Min-lin, et al. Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation[J]. Chinese Journal of Integrative Medicine, 2005,11(2):104-110.
Jian-jun, L., Chang-nan, J., Min-lin, Z. et al. Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation., Chin. J. Integr. Med. 11, 104–110 (2005). https://doi.org/10.1007/BF02836465DOI:
Lin Jian-jun, Jin Chang-nan, Zheng Min-lin, et al. Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation[J]. Chinese Journal of Integrative Medicine, 2005,11(2):104-110. DOI: 10.1007/BF02836465.
Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation
摘要
Objective: To observe the short-term efficacy and safety of Shenqi mixture (SQM) combined with microwave coagulation in treating primary hepatocellular carcinoma (HCC).Methods: Seventy-two patients with primary HCC of stage II – III
Karnofsky scoring ⩾50 scores and predicted survival period ⩾3 months were selected and randomly assigned into two groups
the treated group and the control group
36 in each. Microwave therapy was applied to both groups by double leads
60 W
800 sec once a week for two weeks. To the treated group
SQM was given additionally through oral intake of 20 ml
three times a day for 1 month. The changes in tumor size
main symptoms
serum level of alpha-fetoprotein (AFP)
immune function and adverse reaction were observed after treatment and the immune parameters of the patients were compared with 30 healthy persons in the normal control group.Results: (1) In the SQM treated group
after treatment 3 patients got completely remitted (CR)
24 partial remitted (PR)
4 unchanged (NC) and 5 progressively deteriorated (PD)
the effective rate being 75.00%; while in the control group
1 got CR
19 PR
9 NC and 7 PD
the effective rate being 55.56%. Comparison of the effective rate between the two groups showed significant difference (P<0.05). (2) AFP level decreased after treatment in both groups
but the decrement in the treated group was significantly higher than that in the control group (P<0.01). (3) After treatment
in the treated group
CD3+
CD4+
CD4+/CD8+ and NK activity were improved
Karnofsky scores increased and liver function bettered
with these improvements significantly superior to those in the control group (P<0. 01). (4) The improvement in symptoms such as hepatic region pain
fever
weakness
poor appetite and jaundice in the treated group after treatment was also superior to that in the control group (P<0.01). (5)The 12-month
18-month and 24-month survival rates were higher and the recurrence rate was lower in the treated group than those in the control group
showing significant difference (P<0.05).Conclusion: Combined therapy with SQM and microwave coagulation could not only kill the tumor and residue tumor cells to prevent recurrence
but also enhance the cellular immunity of organism. It is one of the effective therapies for patients with middle-advanced hepatocarcinoma
who have lost the chance of surgical operation. It could improve clinical symptoms
elevate the quality of life
prolong the survival period of patients
but shows no evident adverse reaction.
Abstract
Objective: To observe the short-term efficacy and safety of Shenqi mixture (SQM) combined with microwave coagulation in treating primary hepatocellular carcinoma (HCC).Methods: Seventy-two patients with primary HCC of stage II – III
Karnofsky scoring ⩾50 scores and predicted survival period ⩾3 months were selected and randomly assigned into two groups
the treated group and the control group
36 in each. Microwave therapy was applied to both groups by double leads
60 W
800 sec once a week for two weeks. To the treated group
SQM was given additionally through oral intake of 20 ml
three times a day for 1 month. The changes in tumor size
main symptoms
serum level of alpha-fetoprotein (AFP)
immune function and adverse reaction were observed after treatment and the immune parameters of the patients were compared with 30 healthy persons in the normal control group.Results: (1) In the SQM treated group
after treatment 3 patients got completely remitted (CR)
24 partial remitted (PR)
4 unchanged (NC) and 5 progressively deteriorated (PD)
the effective rate being 75.00%; while in the control group
1 got CR
19 PR
9 NC and 7 PD
the effective rate being 55.56%. Comparison of the effective rate between the two groups showed significant difference (P<0.05). (2) AFP level decreased after treatment in both groups
but the decrement in the treated group was significantly higher than that in the control group (P<0.01). (3) After treatment
in the treated group
CD3+
CD4+
CD4+/CD8+ and NK activity were improved
Karnofsky scores increased and liver function bettered
with these improvements significantly superior to those in the control group (P<0. 01). (4) The improvement in symptoms such as hepatic region pain
fever
weakness
poor appetite and jaundice in the treated group after treatment was also superior to that in the control group (P<0.01). (5)The 12-month
18-month and 24-month survival rates were higher and the recurrence rate was lower in the treated group than those in the control group
showing significant difference (P<0.05).Conclusion: Combined therapy with SQM and microwave coagulation could not only kill the tumor and residue tumor cells to prevent recurrence
but also enhance the cellular immunity of organism. It is one of the effective therapies for patients with middle-advanced hepatocarcinoma
who have lost the chance of surgical operation. It could improve clinical symptoms
elevate the quality of life
prolong the survival period of patients
but shows no evident adverse reaction.
关键词
Primary Hepatocarcinomaintegrated traditional Chinese and Western medicineShenqi mixturemicrowave coagulation
Keywords
Primary Hepatocarcinomaintegrated traditional Chinese and Western medicineShenqi mixturemicrowave coagulation
references
Zhang SW, Li LD, Lu FZ, et al. Survey of morbidity of primary hepatocarcinoma in 1990–1992 in China. Chin J Oncol 1999; 21(4): 245.
Wu MC. Progress of diagnosis and treatment of primary hepatocarcinoma. China Cancer 1999;8(1): 18–20.
Tang ZY, editor. Basic theory and clinics of the metastasis and recurrence of liver cancer. Shanghai: Shanghai Publishing House of Science and Education, 2003: 45–51.
Chinese Antitumor Association. Norms for diagnosis and treatment of often encountered malignant tumor (New Compiled): Primary hepatocarcinoma. Beijing: Combined Publishing House of Beijing Medical University and Peking Union Medical College, 1999: 25–28.
State Administration of TCM. Vocation standard on TCM, P. R. China. Terminology on diagnose, treatment, disease and Syndrome in clinical TCM. Nanjing: Nanjing University Press, 1994: 15, 107.
Luo YZ, Mai WW, Cai MJ. Chemotherapy assisted by strengthing Spleen and regulating Qi in treating 37 patients with hepatocarcinoma of advance stage. J Guangzhou Univ TCM 1997;14(3): 159–162.
Sun Y editor. Medicine of Tumor. Beijing: People’s Medical Publishing House, 2001: 994–996.
Tan KB, Gao YH. Application and progress of ultrasonic guiding microwave coagulation in treatment of hepatocarcinoma. Chin J Ultrasound Med 2000; 16 (5): 390–392.
Liang P, Dong BW, Ding XL, et al. Clinical application of ultrasonic guiding percutaneous microwave coagulation for treatment of hepatocarcinoma. Chin J Oncol 1997;19(6): 448–450.
Ma ZM, Fu YL, editors. Explanation of drugs’ properties in books of materia medica of past dynasties. Beijing: Chinese Publishing House of Medical Sciences and Technology, 2002: 683–684; 684–692; 385–393; 692–701; 202–210; 770–773; 739–748; 727–734; 187; 37–42; 706–715.
Yang CF, Chen XM, Xie W. Study on oxygen free radical scavenging effect of Gel32. Modern Prev Med 1997;24(1): 28.